Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
A technology of inhibitors and chemotherapeutic agents, applied in the field of inhibitors of short-chain dehydrogenase activity for the treatment of coronary artery disease, can solve problems such as myocardial function degradation and myocardial cell death
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0238] Depending on the type of substituents used in the preparation of the 15-PGDH inhibitors as well as the intermediates and the chosen method of preparation, the novel 15-PGDH inhibitors may be in any possible isomeric form, such as substantially pure geometric (cis or trans) isomers, optical isomers (enantiomers) and racemates.
[0239] In some embodiments, 15-PGDH inhibitors of formula (VIII) may include compounds of formula (IX):
[0240]
[0241] and pharmaceutically acceptable salts thereof.
[0242] Advantageously, a 15-PDGH inhibitor of formula (IX) was found to: i) inhibit recombinant 15-PGDH at a concentration of 1 nM; ii) inhibit 15-PGDH in a cell line at a concentration of 100 nM; iii) increase PGE 2 production; iv) is chemically stable in aqueous solutions over a wide pH range; v) is chemically stable when incubated with hepatocyte extracts; vi) is chemically stable when incubated with hepatocyte cell lines; vii) when When injected IP into mice, exhibited...
Embodiment
[0286] This example shows results from a study in which the 15-PGDH inhibitor (+) SW033291 prevented doxorubicin-induced cardiomyopathy in mice. Doxorubicin-induced cardiomyopathy limits the total dose of doxorubicin that can be administered to cancer patients. Prevention of this effect would directly reduce the risk of cardiomyopathy in cancer patients receiving doxorubicin-containing regimens, and would also mean that cancer patients would not have to undergo treatment when total doxorubicin doses reach current cardiotoxicity-based dose limits. Discontinue active doxorubicin-based therapy.
[0287] figure 1 The design of the study is schematically shown in which male C57b16J mice received a cumulative dose of 15 mgk of doxorubicin at 7 doses of 2.15 mpk per day on study days 1 to 7. The 15-PGDH inhibitor (+) SW033291 was administered by oral gavage at a dose of 25 mpk twice daily during days 1-14 of the study as a solution in a vehicle of 10% ethanol and 90% soybean oil. ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com